News and Announcements
The Warburton Global Fund delivers an annualised return since inception of +36%.
- Published May 07, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Series 1 units of the Warburton Global Fund gained 1.6% in April 2018. The value of $1 invested since inception is $1.89.
April was a mixed month for the global financial markets. Government bond prices declined around the world, while most major equity indexes advanced higher. The US yield curve continued to flatten, as US Treasury bonds fell in value at both shorter and longer maturities. Commodity price movements were mixed. Oil prices rose strongly, industrial metal prices firmed and precious metal prices fell. The USD strengthened versus both the AUD and JPY.
The Warburton Global Fund generated a solid month of performance. In aggregate, our commodity and bond positions were positive, while the stronger USD was a drag on performance. In our commodity portfolio, our vanadium holdings performed well and despite the surge in the USD hitting the prices of both copper and gold, oil remained well bid and was our best performer for the month. In our bond portfolio, a short position in two-year US Treasuries proved profitable, as did a long position in US TIPS. Our weighting towards a flatting yield curve also proved correct. While the strengthening USD and the lower equity market volatility contributed to the JPY being our worst performer for the month, losses were offset by gains made shorting the AUD.
About Warburton Global Fund
Warburton Investment Management manages client capital via the Warburton Global Fund, a global macro hedge fund that deals in international investments. The fund invests in public equity, fixed income, currency and commodity markets worldwide.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
